Speaker(s): 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Recognize and screen for the 14 modifiable risk factors for dementia as outlined by the Lancet Commission, with an emphasis on incorporating risk reduction strategies into routine clinical care.
2. Explain the role of the apolipoprotein E (ApoE) genotype in dementia risk, including its implications for personalized risk assessment and patient counseling.
3. Integrate clinical strategies to evaluate patients at risk for diseases such as Alzheimer’s, Parkinson’s and Lewy Body Dementia including cognitive screenings and laboratory testing.
4. Describe the current and emerging landscape of blood-based biomarkers for neurodegenerative diseases, including their clinical utility, limitations, and role in early detection and prevention.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Chichun Emily Sun DO and Karen Tillotson, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:

None.